BioLife Financial Statements From 2010 to 2025
| BLFE Stock | USD 0.0001 0.00 0.00% |
Check BioLife Sciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioLife Sciences' main balance sheet or income statement drivers, such as , as well as many indicators such as . BioLife financial statements analysis is a perfect complement when working with BioLife Sciences Valuation or Volatility modules.
BioLife |
BioLife Sciences Company Cash And Equivalents Analysis
BioLife Sciences' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current BioLife Sciences Cash And Equivalents | 15.62 K |
Most of BioLife Sciences' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioLife Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, BioLife Sciences has 15.62 K in Cash And Equivalents. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Medical Instruments & Supplies industry. The cash and equivalents for all United States stocks is 100.0% higher than that of the company.
BioLife Sciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioLife Sciences's current stock value. Our valuation model uses many indicators to compare BioLife Sciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioLife Sciences competition to find correlations between indicators driving BioLife Sciences's intrinsic value. More Info.BioLife Sciences is rated below average in current valuation category among its peers. It is number one stock in price to sales category among its peers . The ratio of Current Valuation to Price To Sales for BioLife Sciences is about 1,013,638,000 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioLife Sciences' earnings, one of the primary drivers of an investment's value.About BioLife Sciences Financial Statements
BioLife Sciences stakeholders use historical fundamental indicators, such as BioLife Sciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although BioLife Sciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in BioLife Sciences' assets and liabilities are reflected in the revenues and expenses on BioLife Sciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BioLife Sciences. Please read more on our technical analysis and fundamental analysis pages.
Bio Life Sciences Corp. develops, licenses, and distributes antibacterial products and non-contact human temperature screening technology. Bio Life Sciences Corp. was incorporated in 2018 and is based in Mississauga, Canada. Biolife Sciences operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 3 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in BioLife Pink Sheet
BioLife Sciences financial ratios help investors to determine whether BioLife Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLife with respect to the benefits of owning BioLife Sciences security.